Veterinary CRO and CDMO Market is Expected to Elevate to a Value of CAGR of 9% by the End of 2030:Medi-tech Insights

Global Veterinary CRO and CDMO Market: A Comprehensive Analysis

The global veterinary CRO and CDMO market is poised for strong expansion, projected to grow at a rate of 9% over the next five years. This momentum is attributed to a combination of structural industry shifts and evolving needs within the animal health ecosystem.

Year-End Mega Sale: Get Up to 10% Off on All Market Research Reports

Rising companion-animal healthcare spending, the advent of complex and specialized modalities, increasing pressure on animal health companies to shorten development timelines, and a growing preference for integrated platform-based outsourcing models are all shaping the trajectory of this market. As animal health companies face heightened competition and increasing R&D demands, the reliance on external partners—particularly CROs and CDMOs—continues to deepen across the value chain.

Overview

Veterinary contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) play a pivotal role in supporting the development, testing, and commercialization of veterinary therapeutics, vaccines, and biologics. CROs primarily concentrate on the research and regulatory elements, including preclinical evaluations, safety and toxicology assessments, and clinical trials for new veterinary drug candidates. They also provide expertise in navigating regulatory frameworks, ensuring that studies meet both global and country-specific standards. On the other hand, CDMOs specialize in formulation development, analytical method development, process optimization, scale-up, and GMP-compliant manufacturing of veterinary products. Together, these organizations enable animal health companies to streamline operations, access specialized capabilities, and align resources toward strategic priorities, ultimately accelerating innovation and time-to-market.

A key benefit of veterinary CROs and CDMOs is their ability to mitigate challenges related to limited infrastructure, scarcity of specialized technical talent, and the high capital investments required for advanced R&D and manufacturing. Outsourcing gives companies the flexibility to manage fluctuating workload demands, reduce operational risks, and benefit from multidisciplinary expertise that would otherwise be difficult to cultivate internally. This model not only enhances efficiency but also contributes to expanding global access to high-quality veterinary medicines and biologics.

Rapid Growth in Companion-Animal Healthcare Spending to Drive Market Growth

One of the most significant drivers of the veterinary CRO and CDMO market is the steady rise in companion-animal healthcare spending worldwide. As pet ownership increases and the human–animal bond strengthens, pet owners are seeking more sophisticated and personalized medical care for their animals. This includes advanced therapies such as next-generation vaccines, biologics, monoclonal antibodies, and targeted treatments for chronic and complex diseases including cancer, dermatological disorders, and immune-mediated conditions.

In the United States, spending on pets has surged dramatically, with total pet industry expenditures increasing by approximately 46% between 2020 and 2024. Spending specifically on pet health and health-related products rose by nearly 25% during the same period, underscoring a shift toward preventive care, advanced diagnostics, and specialty therapeutics. With rising disposable incomes and growing willingness to invest in high-quality care, animal health companies are under pressure to maintain a robust pipeline and bring innovative therapies to market rapidly.

To meet these expectations, companies are heavily relying on CROs and CDMOs for preclinical studies, R&D support, clinical testing of new molecular entities, and manufacturing of both small-molecule and biologic therapies. Outsourcing not only reduces internal workload but also contributes to faster approvals and broader market availability of veterinary medicines. This ongoing shift is expected to remain a strong catalyst for market growth globally.

Growing Consolidation & Preference for Platform Service to Boost Market Growth

Another defining trend is the rapid consolidation within the veterinary CRO and CDMO industry. Mergers, acquisitions, and strategic partnerships are reshaping the competitive landscape, enabling service providers to expand capabilities, geographic presence, and technological expertise. This consolidation supports the development of comprehensive platform-based service models that streamline processes across the product lifecycle—from research and discovery to regulatory support and commercial manufacturing.

Animal health companies increasingly prefer these platform offerings because they reduce operational complexity and eliminate the need to work with multiple fragmented vendors. Integrated service models enhance coordination, generate cost efficiencies, and help companies maintain consistent quality across all stages of development and production. Furthermore, consolidated service providers often offer advanced digital tools, global regulatory expertise, and robust project management capabilities that strengthen client confidence.

As consolidation continues, CROs and CDMOs with broad, end-to-end capabilities are well-positioned to attract larger client portfolios, support more diverse pipelines, and drive sustained growth across the market.

Competitive Landscape Analysis

The veterinary CRO and CDMO market features a mix of mature global players and emerging specialized organizations supporting a wide array of research, development, and manufacturing needs. Key companies active in the market include:

• Charles River Laboratories
• Clinglobal
• Argenta Holdco Limited
• knoell Germany GmbH
• OCRvet
• Veterinary Research Management
• VETSPIN SRL
• Vetio
• TriRx Pharmaceutical Services
• Tekrolab

Across the industry, companies are investing in capability expansion, geographic diversification, new service technologies, and collaboration-driven innovation. Key strategies include expanding laboratory and manufacturing footprints, launching novel service platforms, and forming partnerships that combine scientific, regulatory, and commercial strengths.

Market Drivers

Rapid growth in companion-animal healthcare spending
Rise of complex modalities
Growing pressure to shorten time-to-market & control R&D costs
Growing consolidation & preference for platform service models

Attractive Opportunities

Biologics, monoclonal antibodies and novel vaccines
Geographic expansion and local manufacturing in emerging markets
Platform and verticalized/end-to-end service offerings
Data services and real-world evidence

This evolving landscape signals a transformative period ahead for the veterinary CRO and CDMO market. Growing demand for advanced therapies, increasing outsourcing dependency, and the shift toward integrated platforms will continue to create significant opportunities for service providers worldwide.

Key Request a free sample copy or view report summary: https://meditechinsights.com/veterinary-cro-and-cdmo-market/request-sample/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.